Sight Sciences, Inc. SGHT
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
-5.95
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $77.4M | -$38.4M | $66.7M | -$29.9M | $63.9M |
| 2024 | $79.9M | -$51.5M | $68.3M | -$22.7M | $87.5M |
| 2023 | $81.1M | -$55.5M | $69.2M | -$48.0M | $120.2M |
| 2022 | $71.3M | -$86.2M | $59.0M | -$76.9M | $160.1M |
| 2021 | $49.0M | -$63.0M | $40.3M | -$53.4M | $232.1M |
| 2020 | $27.6M | -$34.7M | $18.4M | -$33.1M | -$88.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Encrantz Staffan | director | 2026-06-10 | Buy | 14,100 | $4.88 |
| Fountain Tamara | director | 2026-06-04 | Grant | 28,261 | — |
| Encrantz Staffan | director | 2026-06-04 | Grant | 28,261 | — |
| Burbach Gerhard F | director | 2026-06-04 | Grant | 28,261 | — |
| Zurbay Donald | director | 2026-06-04 | Grant | 28,261 | — |
| Mazzacco Catherine | director | 2026-06-04 | Grant | 28,261 | — |
| Bauerlein Alison | Chief Operating Officer | 2026-05-18 | Sell | 12,728 | $5.12 |
| Rodberg James | Chief Financial Officer | 2026-04-06 | Sell | 7,231 | $3.55 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.95 (distress)
- Working capital / assets 0.882
- Retained earnings / assets -3.337
- EBIT / assets -0.322
- Equity / liabilities 1.245
Source: SEC EDGAR filings · CIK 0001531177 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.